Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilta-cel versus PVd or DPd in relapsed lenalidomide-refractory multiple myeloma
NL-OMON60239Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Sep 2020; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60239.